Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors

被引：0
|
作者：
Henrich, T. J. [1 ,2 ]
Lewine, N. [3 ]
Lee, S-H [1 ,4 ]
Rao, S. [3 ]
Berro, R. [5 ]
Greaves, W. [6 ]
Gulick, R.
Tsibris, A. [2 ,7 ]
Moore, J. [5 ]
Kuritzkes, D. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Harvard Univ, Cambridge, MA 02138 USA
[4] Pusan Natl Univ, Pusan, South Korea
[5] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[6] Schering Plough Res Inst, Kenilworth, NJ USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
ANTIVIRAL THERAPY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
46
引用
收藏
页码：A59 / A59
页数：1
相关论文
共 50 条
  • [41] Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
    Mohamed, Hager
    Gurrola, Theodore
    Berman, Rachel
    Collins, Mackenzie
    Sariyer, Ilker K.
    Nonnemacher, Michael R.
    Wigdahl, Brian
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [42] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [43] CCR5 genotype and resistance to vertical transmission of HIV-1
    Philpott, S
    Burger, H
    Charbonneau, T
    Grimson, R
    Vermund, SH
    Visosky, A
    Nachman, S
    Kovacs, A
    Tropper, P
    Frey, H
    Weiser, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193
  • [44] CCR5 promoter polymorphism and HIV-1 disease progression
    McDermott, DH
    Zimmerman, PA
    Guignard, F
    Kleeberger, CA
    Leitman, SF
    Murphy, PM
    LANCET, 1998, 352 (9131): : 866 - 870
  • [45] CCR5, vertical transmission of HIV-1, and disease progression
    Bailey, AJ
    Newell, ML
    De Rossi, A
    Giaquinto, C
    Iasci, A
    Ravizza, M
    Garcia-Rodriguez, MC
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (02): : 211 - 212
  • [46] The promise of CCR5 antagonists as new therapies for HIV-1
    Repik, Alexander
    Richards, Kathryn H.
    Clapham, Paul R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139
  • [47] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [48] Small-molecule CCR5 Ligands that may Spare the CCR5 Function Opportunity for New Antiviral Discovery?
    Kazmierski, Wieslaw
    Muniz-Medina, Vanessa
    Danehower, Susan
    Jones, Stacey
    Kenakin, Terry
    ANTIVIRAL RESEARCH, 2009, 82 (02) : A43 - A43
  • [49] A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
    Dragic, T
    Trkola, A
    Thompson, DAD
    Cormier, EG
    Kajumo, FA
    Maxwell, E
    Lin, SW
    Ying, WW
    Smith, SO
    Sakmar, TP
    Moore, JP
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5639 - 5644
  • [50] Association between CCR5 genotype and the clinical course of HIV-1 infection
    Husman, AMD
    Koot, M
    Cornelissen, M
    Keet, IPM
    Brouwer, M
    Broersen, SM
    Bakker, M
    Roos, MTL
    Prins, M
    deWolf, F
    Coutinho, RA
    Miedema, F
    Goudsmit, J
    Schuitemaker, H
    ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 882 - +
12345